Pfizer and BioNTech announced Monday their coronavirus vaccine was more than 90% effective in preventing COVID-19 among those without evidence of prior infection, hailing the development as “a great ...
Stocktwits on MSN
TRAW stock slides in volatile session – what’s the latest on its phase 2 trial for COVID-19 treatment?
The open-label trial enrolled 90 patients and compared Ratutrelvir with Paxlovid, an oral antiviral medication from Pfizer.
Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...
Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Tuesday Pfizer announced it's expanding its clinical trials for younger children ages 5 to 11-years-old. Medical doctors are calling this the final frontier. This is a 2-year study, where a subset of ...
At the time of this analysis, the Braftovi combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response ...
Pfizer vaccine fails to provide expected immunity for kids ages 2-5 in trials; Extra dose now tested
Vaccine maker Pfizer said Friday that trials of its vaccine in children ages 2 to 5 show that it did not provide the expected immunity in kids this age, and it is adding a third dose to the regimen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results